Back to Search
Start Over
A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe.
- Source :
-
Parasites & vectors [Parasit Vectors] 2017 Nov 01; Vol. 10 (1), pp. 531. Date of Electronic Publication: 2017 Nov 01. - Publication Year :
- 2017
-
Abstract
- Background: Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days. A study was undertaken in Europe to confirm lotilaner's safety and anti-tick efficacy in client-owned dogs.<br />Methods: In this assessor-blinded study, dogs were enrolled at 19 clinics in Germany, Hungary and Portugal. Qualifying households with no more than three dogs were randomized in an approximate 2:1 ratio to a lotilaner or fipronil/(S)-methoprene (FSM) (Frontline® Combo Spot-on, Merial) treatment group. One household dog with at least three live attached ticks was the primary dog. Treatments were dispensed Days 0, 28 (± 2) and 56 (± 2) for owner administration to all household dogs. Tick counts were performed on primary dogs Days 7 (± 1), and ±2 days on Days 14, 21, 28, 42, 56, 70 and 84; supplementary dogs were assessed for safety ± 2 days on Days 28, 56 and 84. Efficacy was assessed by comparing mean Day 0 live attached tick counts with subsequent counts.<br />Results: The most frequently retrieved ticks were Ixodes ricinus, Dermacentor reticulatus and Rhipicephalus sanguineus (sensu lato), with Ixodes hexagonus also present. In the lotilaner group (n = 127) geometric mean tick count reductions were at least 98% from the first post-treatment visit (Day 7) through Day 56, when efficacy was 100%. For FSM (n = 68), efficacy remained at least 96% through Day 84, but at no point were all dogs free of live attached ticks. Mean counts in lotilaner-treated dogs were significantly lower than FSM-treated dogs on Days 7, 42, 70 and 84 (P < 0.05). Percent efficacy over all post-enrolment visits was 99.3 and 98.3% for lotilaner and FSM groups, respectively (t <subscript>(190)</subscript>  = 2.23, P = 0.0268). Owners successfully administered all treatments, and both products were well-tolerated.<br />Conclusion: Under European field conditions, lotilaner flavoured chewable tablets administered monthly, were > 98% effective in eliminating live ticks from the first post-treatment assessment (Day 7) through Day 56 and maintained 100% of dogs tick-free on Days 70 and 84. Lotilaner was safe, providing superior tick control to FSM administered according to the same schedule.
- Subjects :
- Acaricides administration & dosage
Acaricides adverse effects
Administration, Oral
Animals
Dermacentor drug effects
Dog Diseases parasitology
Dogs
Europe
Female
Male
Pyrazoles administration & dosage
Pyrazoles adverse effects
Pyrazoles therapeutic use
Rhipicephalus drug effects
Tablets administration & dosage
Tablets adverse effects
Tick Infestations parasitology
Tick Infestations veterinary
Acaricides therapeutic use
Dog Diseases drug therapy
Ixodes drug effects
Tick Infestations drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1756-3305
- Volume :
- 10
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Parasites & vectors
- Publication Type :
- Academic Journal
- Accession number :
- 29089058
- Full Text :
- https://doi.org/10.1186/s13071-017-2478-9